Penn Cancer Center Sponsors Exhibit of Cancer Patients’ Art

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

PHILADELPHIA-“Confronting Cancer Through Art” is a juried exhibition of inspirational artwork crafted by individuals who have been touched by cancer (see artwork). This year marks the second time that the University of Pennsylvania Cancer Center has sponsored this exhibit, which runs through October 31, 1999, at the Arthur Ross Gallery in Philadelphia. The first exhibit was presented in 1996.

PHILADELPHIA—“Confronting Cancer Through Art” is a juried exhibition of inspirational artwork crafted by individuals who have been touched by cancer (see artwork). This year marks the second time that the University of Pennsylvania Cancer Center has sponsored this exhibit, which runs through October 31, 1999, at the Arthur Ross Gallery in Philadelphia. The first exhibit was presented in 1996.

 “Artmaking encourages vision, hope, and imagination, all of which foster the healing process,” said Gianna Volpe, MFA, who directs the Cancer Center’s Art Program and whose own artwork is part of the exhibit. The exhibit contains 65 pieces created in various media, including sculpture, quilting, painting, and photography. It can be viewed online until October 31, 1999, at the Center’s website: www.oncolink.upenn.edu.

Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content